(주)모아바이오

Antibody System

[Antibodysystem] Eldelumab ELISA Kit

Cat-No. KDC01901

AntibodySystem는 Primary Antibody Biosimilar - Research Grade

제품을 전문적으로 생산하는 20년의 경험이 있는 High Quality 제조사입니다.

제품 설명

Eldelumab ELISA Kit

제품 번호

KDC01901

제품 특징

Catalog No.

KDC01901

Stability and Storage

The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.

Detection method

Colorimetric

Precision

CV<20%

Sample type

Plasma, Serum

Assay type

Quantitative

Sensitivity

0.156 μg/ml

Range

0.31-5 μg/mL

Recovery

80-120%

Specifications

Eldelumab

Alternative Names

BMS-936557, MDX-1100, CAS: 946414-98-8

Background

Eldelumab (alternative identifier BMS-936557) is a fully human monoclonal antibody (type IgG1 kappa) that targets chemokine (CXC motif) ligand 10 (CXCL10)/Interferon-γ-inducible protein-10 (IP-10). This drug was developed by Bristol-Myers Squibb and Medarex and designed for the treatment of Crohn's disease and ulcerative colitis. To date, eldelumab has been investigated as an induction and maintenance therapy in active Crohn's disease, and its induction treatment demonstrated trends towards clinical and endoscopic efficacy with no new safety signal in a phase IIa study. Meanwhile, inhibiting IP-10 activity through the use of the monoclonal antibody, eldelumab, demonstrated efficacy in patients who achieved high serum concentrations in this phase II, randomized, controlled, proof-of-concept study of moderate-to-severe ulcerative colitis.